Ubiquitin-independent proteasomal degradation during oncogenic viral infections

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 2, 2011, Pages 147-157

  Hwang, Jiwon ^a   Winkler, Laura ^a   Kalejta, Robert F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Oncogenic viruses; Proteasome; Ubiquitin independent

Indexed keywords

DOUBLE STRANDED DNA; PROTEASOME; PROTEIN P53; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SINGLE STRANDED DNA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; VIRUS DNA;

AMINO TERMINAL SEQUENCE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME DEFECT; ENZYME DEGRADATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PARVOVIRUS; PARVOVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA VIRUS; TUMOR VIRUS; VIRUS INFECTION; WART VIRUS;

EUKARYOTA;

EID: 79959265889     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.05.005     Document Type: Review

References (165)

1. N. Chondrogianni, E.S. Gonos, Proteasome function determines cellular homeostasis and the rate of aging, Adv. Exp. Med. Biol. 694 (2010) 38-46.
2. D.J. Klionsky, S.D. Emr, Autophagy as a regulated pathway of cellular degradation, Science 290 (2000) 1717-1721.
3. B. Levine, G. Kroemer, Autophagy in the pathogenesis of disease, Cell 132 (2008) 27-42.
4. S.H. Lecker, A.L. Goldberg, W.E. Mitch, Protein degradation by the ubiquitin-proteasome pathway in normal and disease states, J. Am. Soc. Nephrol. 17 (2006) 1807-1819.
5. K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, A.L. Goldberg, Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules, Cell 78 (1994) 761-771.
6. T. Jung, B. Catalgol, T. Grune, The proteasomal system, Mol. Aspects Med. 30 (2009) 191-296.
7. K.I. Nakayama, K. Nakayama, Ubiquitin ligases: cell-cycle control and cancer, Nat. Rev. Cancer 6 (2006) 369-381.
8. M. Muratani, W.P. Tansey, How the ubiquitin-proteasome system controls transcription, Nat. Rev. Mol. Cell Biol. 4 (2003) 192-201.
9. N.J. Krogan, M.H.Y. Lam, J. Fillingham, M.-C. Keogh, M. Gebbia, J. Li, N. Datta, G. Cagney, S. Buratowski, A. Emili, J.F. Greenblatt, Proteasome involvement in the repair of DNA double-strand breaks, Mol. Cell 16 (2004) 1027-1034.
10. R.Z. Orlowski, The role of the ubiquitin-proteasome pathway in apoptosis, Cell Death Differ. 6 (1999) 303-313.
11. J. Adams, The proteasome: a suitable antineoplastic target, Nat. Rev. Cancer 4 (2004) 349-360.
12. P.M. Voorhees, E.C. Dees, B. O'Neil, R.Z. Orlowski, The proteasome as a target for cancer therapy, Clin. Cancer Res. 9 (2003) 6316-6325.
13. P. Blanchette, P.E. Branton, Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses, Virology 384 (2009) 317-323.
14. M. Petroski, The ubiquitin system, disease, and drug discovery, BMC Biochem. 9 (2008) S7.
15. J. Loureiro, H.L. Ploegh, Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions, in: W.A. Frederick (Ed.), Advances in Immunology, vol. 92, Academic Press, 2006, pp. 225-305.
16. M.H. Glickman, A. Ciechanover, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction, Physiol. Rev. 82 (2002) 373-428.
17. I. Jariel-Encontre, G. Bossis, M. Piechaczyk, Ubiquitin-independent degra- dation of proteins by the proteasome, Biochim. Biophys. Acta 1786 (2008) 153-177.
18. H.M. Kim, Y. Yu, Y. Cheng, Structure characterization of the 26S proteasome, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1809 (2011) 67-79.
19. M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H.D. Bartunik, R. Huber, Structure of 20S proteasome from yeast at 2.4 Å resolution, Nature 386 (1997) 463-471.
20. M. Groll, M. Bajorek, A. Kohler, L. Moroder, D.M. Rubin, R. Huber, M.H. Glickman, D. Finley, A gated channel into the proteasome core particle, Nat. Struct. Mol. Biol. 7 (2000) 1062-1067.
21. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, T. Tsukihara, The structure of the mammalian 20S Proteasome at 2.75 Å resolution, Structure, 10, 2002, pp. 609-618.
22. M. Rechsteiner, C.P. Hill, Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors, Trends Cell Biol. 15 (2005) 27-33.
23. L. Bedford, S. Paine, P.W. Sheppard, R.J. Mayer, J. Roelofs, Assembly, structure, and function of the 26S proteasome, Trends Cell Biol. 20 (2010) 391-401.
24. L. Kuehn, B. Dahlmann, Structural and functional properties of proteasome activator PA28, Mol. Biol. Rep. 24 (1997) 89-93.
25. K.Sadre-Bazzaz, F.G.Whitby, H.Robinson, T. Formosa, C.P. Hill, Structureof a Blm10 complex reveals common mechanisms for proteasome binding and gate opening, Mol. Cell 37 (2010) 728-735.
26. J. Blickwedehl, M. Agarwal, C. Seong, R.K. Pandita, T. Melendy, P. Sung, T.K. Pandita, N. Bangia, Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability, Proc. Natl. Acad. Sci. 105 (2008) 16165-16170.
27. P. Xu, D.M. Duong, N.T. Seyfried, D. Cheng, Y. Xie, J. Robert, J. Rush, M. Hochstrasser, D.Finley,J.Peng,Quantitativeproteomicsrevealsthefunc- tion of unconventional ubiquitin chains in proteasomal degradation, Cell 137 (2009) 133-145.
28. M. Koegl, T. Hoppe, S. Schlenker, H.D. Ulrich, T.U. Mayer, S. Jentsch, A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly, Cell 96 (1999) 635-644.
29. K. Husnjak, S. Elsasser, N. Zhang, X. Chen, L. Randles, Y. Shi, K. Hofmann, K.J. Walters, D. Finley, I. Dikic, Proteasome subunit Rpn13 is a novel ubiquitin receptor, Nature 453 (2008) 481-488.
30. S. Elsasser, D. Chandler-Militello, B. Müller, J. Hanna, D. Finley, Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome, J. Biol. Chem. 279 (2004) 26817-26822.
31. D. Finley, Recognition and processing of ubiquitin-protein conjugates by the proteasome, Annu. Rev. Biochem. 78 (2009) 477-513.
32. A. Peth, T. Uchiki, A.L. Goldberg, ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation, Mol. Cell 40 (2010) 671-681.
33. B. Ruggeri, S. Miknyoczki, B. Dorsey, A.-M. Hui, The development and pharmacol- ogy of proteasome inhibitors for the management and treatment of cancer, in: S.J. Enna, W. Michael (Eds.), Advances in Pharmacology, vol. 57, Academic Press, 2009, pp. 91-135.
34. S. Imajoh-Ohmi, T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura, H. Kikuchi, Lactacystin, a specic inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells, Biochem. Biophys. Res. Commun. 217 (1995) 1070-1077.
35. E. Fujita, T. Mukasa, T. Tsukahara, K. Arahata, S. Omura, T. Momoi, Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors, Biochem. Biophys. Res. Commun. 224 (1996) 74-79.
36. C.A. Moody, L.A. Laimins, Human papillomavirus oncoproteins: pathways to transformation, Nat. Rev. Cancer 10 (2010) 550-560.
37. E.W. Harhaj, N.S. Harhaj, Mechanisms of persistent NF-kappaB activation by HTLV-I tax, IUBMB Life 57 (2005) 83-91.
38. B.D. Grifn, M.C. Verweij, E.J.H.J. Wiertz, Herpesviruses and immunity: the art of evasion, Vet. Microbiol. 143 (2010) 89-100.
39. A.N. Antoniou, S.J. Powis, Pathogen evasion strategies for the major histocompat- ibility complex class I assembly pathway, Immunology 124 (2008) 1-12.
40. P. Sdek, H. Ying, D.L.F. Chang, W. Qiu, H. Zheng, R. Touitou, M.J. Allday, Z.-X. Jim Xiao, MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein, Mol. Cell 20 (2005) 699-708.
41. Y. Jin,H. Lee,S .X. Zeng, M.-S. Dai, H. Lu, MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation, EMBO J. 22 (2003) 6365-6377.
42. Y. Murakami, S. Matsufuji, T. Kameji, S.-i. Hayashi, K. Igarashi, T. Tamura, K. Tanaka, A. Ichihara, Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination, Nature 360 (1992) 597-599.
43. M. Zhang, C.M. Pickart, P. Cofno, Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate, EMBO J. 22 (2003) 1488-1496.
44. J. Takeuchi, H. Chen, M.A. Hoyt, P. Cofno, Structural elements of the ubiquitin- independent proteasome degron of ornithine decarboxylase, Biochem. J. 410 (2008) 401-407.
45. X. Li, D.M. Lonard, S.Y. Jung, A. Malovannaya, Q. Feng, J. Qin, S.Y. Tsai, M.J. Tsai, B.W. O'Malley, The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP- independent manner by the REGgamma proteasome, Cell 124 (2006) 381-392.
46. X. Li, L. Amazit, W. Long, D.M. Lonard, J.J. Monaco, B.W. O'Malley, Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway, Mol. Cell 26 (2007) 831-842.
47. X. Chen, L.F. Barton, Y. Chi, B.E. Clurman, J.M. Roberts, Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome, Mol. Cell 26 (2007) 843-852.
48. K. Moriishi, T. Okabayashi, K. Nakai, K. Moriya, K. Koike, S. Murata, T. Chiba, K. Tanaka, R. Suzuki, T. Suzuki, T. Miyamura, Y. Matsuura, Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein, J. Virol. 77 (2003) 10237-10249.
49. B.M. Stadtmueller, C.P. Hill, Proteasome activators, Mol. Cell 41 (2011) 8-19.
50. J.W. Shay, W.E. Wright, H. Werbin, Dening the molecular mechanisms of human cell immortalization, Biochim. Biophys. Acta (BBA) - Rev. Cancer 1072 (1991) 1-7.
51. P.S. Moore, Y. Chang, Why do viruses cause cancer? Highlights of the rst century of human tumour virology, Nat. Rev. Cancer 10 (2010) 878-889.
52. H. zur Hausen, Papillomaviruses in the causation of human cancers - a brief historical account, Virology 384 (2009) 260-265.
53. M. Michaelis, H.W. Doerr, J. Cinatl, The story of human cytomegalovirus and cancer: increasing evidence and open questions, Neoplasia 11 (2009) 1-9.
54. J. Cinatl Jr., J.U. Vogel, R. Kotchetkov, H. Wilhelm Doerr, Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression, FEMS Microbiol. Rev. 28 (2004) 59-77.
55. H. zur Hausen, Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis, J. Natl. Cancer Inst. 92 (2000) 690-698.
56. S.N. Boyer, D.E. Wazer, V. Band, E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome path- way, Cancer Research 56 (1996) 4620-4624.
57. A. Felsani, A.M. Mileo, M.G. Paggi, Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins, Oncogene 25 (2006) 5277-5285.
58. J.D. Morris, T. Crook, L.R. Bandara, R. Davies, N.B. LaThangue, K.H. Vousden, Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling, Oncogene 8 (1993) 893-898.
59. K. Huh, X. Zhou, H. Hayakawa, J.-Y. Cho, T.A. Libermann, J. Jin, J. Wade Harper, K. Munger, Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor, J. Virol. 81 (2007) 9737-9747.
60. M. Scheffner, B. Werness, J. Huibregtse, A. Levine, P. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell 63 (1990) 1129-1136.
61. K.H. Vousden, X. Lu, Live or let die: the cell's response to p53, Nat. Rev. Cancer 2 (2002) 594-604.
62. A.J. Levine, J. Momand, C.A. Finlay, The p53 tumour suppressor gene, Nature 351 (1991) 453-456.
63. M.Hollstein,D.Sidransky,B.Vogelstein,C.Harris,p53mutationsinhuman cancers, Science 253 (1991) 49-53.
64. C.J. Brown, S. Lain, C.S. Verma, A.R. Fersht, D.P. Lane, Awakening guardian angels: drugging the p53 pathway, Nat. Rev. Cancer 9 (2009) 862-873.
65. Y. Haupt, R. Maya, A. Kazaz, M. Oren, Mdm2 promotes the rapid degradation of p53, Nature 387 (1997) 296-299.
66. M. Scheffner, J. Huibregtse, R. Vierstra, P. Howley, The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53, Cell 75 (1993) 495-505.
67. S. Camus, S. Menendez, C.F. Cheok, L.F. Stevenson, S. Lain, D.P. Lane, Ubiquitin- independent degradation of p53 mediated by high-risk human papillomavirus protein E6, Oncogene 26 (2007) 4059-4070.
68. X.Li,P.Cofno, High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determinesdegradation, J.Virol.70(1996) 4509-4516.
69. S. Landolfo, M. Gariglio, G. Gribaudo, D. Lembo, The human cytomegalovirus, Pharmacol. Ther. 98 (2003) 269-297.
70. E.S. Mocarski, T. Shenk, R.F. Pass, Cytomegaloviruses, in: D.M. Knipe, P.M. Howley (Eds.), Fields Virology, Lippincott, Philadelphia, 2007, pp. 2701-2772.
71. L.E. Harkins, L.A. Matlaf, L. Soroceanu, K. Klemm, W.J. Britt, W. Wang, K.I. Bland, C.S. Cobbs, Detection of human cytomegalovirus in normal and neoplastic breast epithelium, Herpesviridae 1 (2010) 8.
72. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646-674.
73. E. Slinger, E. Langemeijer, M. Siderius, H.F. Vischer, M.J. Smit, Herpesvirus-encoded GPCRs rewire cellular signaling, Mol. Cell. Endocrinol. 331 (2011) 179-184.
74. A.D. Yurochko, Human cytomegalovirus modulation of signal transduction, Curr. Top. Microbiol. Immunol. 325 (2008) 205-220.
75. V. Sanchez, D.H. Spector, Subversion of cell cycle regulatory pathways, Curr. Top. Microbiol. Immunol. 325 (2008) 243-262.
76. A.J. Hume, R.F. Kalejta, Regulation of the retinoblastoma proteins by the human herpesviruses, Cell Div. 4 (2009) 1.
77. A. Loewendorf, C.A. Benedict, Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything, J. Int. Med. 267 (2010) 483-501.
78. T. Crough, R. Khanna, Immunobiology of human cytomegalovirus: from bench to bedside, Clin. Microbiol. Rev. 22 (2009) 76-98.
79. K. Strååt, C. Liu, A. Rahbar, Q. Zhu, L. Liu, N. Wolmer-Solberg, F. Lou, Z. Liu, J. Shen, J. Jia, S. Kyo, M. Björkholm, J. Sjöberg, C. Söderberg-Nauclér, D. Xu, Activation of telomerase by human cytomegalovirus, J. Natl. Cancer Inst. 101 (2009) 488-497.
80. W. Britt, Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease, Curr. Top. Microbiol. Immunol. 325 (2008) 417-470.
81. J. Vomaske, S. Varnum, R. Melnychuk, P. Smith, L. Pasa-Tolic, J.I. Shutthanandan, D.N. Streblow, HCMV pUS28 initiates pro-migratory signaling via activation of Pyk2 kinase, Herpesviridae 1 (2010) 2.
82. G.Chan, M.T. Nogalski, A.D. Yurochko, ActivationofEGFRonmonocytesis required for human cytomegalovirus entry and mediates cellular motility, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 22369-22374.
83. P. Caposio, S.L. Orloff, D.N. Streblow, The role of cytomegalovirus in angiogenesis, Virus Res. 157 (2010) 204-211.
84. E.A. Fortunato, M.L. Dell'Aquila, D.H. Spector, Specic chromosome 1 breaks induced by human cytomegalovirus, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 853-858.
85. Y. Shen, H. Zhu, T. Shenk, Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins, Proc. Natl. Acad. Sci. 94 (1997) 3341-3345.
86. V.K. Siew, C.Y. Duh, S.K. Wang, HumancytomegalovirusUL76induces chromosome aberrations, J. Biomed. Sci. 16 (2009) 107.
87. W. Brune, Inhibition of programmed cell death by cytomegaloviruses, Virus Res. 157 (2010) 144-150.
88. C.M. Spencer, X.L. Schafer, N.J. Moorman, J. Munger, Human cytomegalovirus induces the activity and expression of acetyl-CoA carboxylase, a fatty acid biosynthetic enzyme whose inhibition attenuates viral replication, J. Virol. 85 (2011) 5814-5824.
89. J.W. Chambers, T.G. Maguire, J.C. Alwine, Glutamine metabolism is essential for human cytomegalovirus infection, J. Virol. 84 (2010) 1867-1873.
90. R.F. Kalejta, Tegument proteins of human cytomegalovirus, Microbiol. Mol. Biol. Rev. 72 (2008) 249-265.
91. H. Hofmann, H. Sindre, T. Stamminger, Functional interaction between the pp 71 protein of human cytomegalovirus and the PML-interacting protein human Daxx, J. Virol. 76 (2002) 5769-5783.
92. S. R. Cantrell, W. A. Bresnahan, Interaction between the human cytomega- lovirus UL82 gene product (pp71) and hDaxx regulates immediate-early gene expression and viral replication, J. Virol. 79 (2005) 7792-7802.
93. S. Lee, R.F. Kalejta, J.A. Kerry, O.J. Semmes, C. O'Connor, Z. Kahn, B. Garcia, T. Shenk, E. Murphy, BclAF1 restriction factor neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection, (Unpublished Results).
94. R.F. Kalejta, J.T. Bechtel, T. Shenk, Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors, Mol. Cell. Biol. 23 (2003) 1885-1895.
95. R.T. Saffert, R.F. Kalejta, Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression, J. Virol. 80 (2006) 3863-3871.
96. A.J.Hume,J.S.Finkel,J.P.Kamil,D.M.Coen,M.R.Culbertson,R.F.Kalejta, Phosphorylation of retinoblastoma protein by viral protein with cyclin- dependent kinase function, Science 320 (2008) 797-799.
97. R.F. Kalejta, T. Shenk, Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71p rotein, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3263-3268.
98. J. Hwang, R.F. Kalejta, Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus- infected cells, Virology 367 (2007) 334-338.
99. S.Bhattacharya, J. Garriga, J. Calbo, T. Yong, D.S. Haines, X. Grana,SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells, Oncogene 22 (2003) 2443-2451.
100. J. Herrmann, L.O. Lerman, A. Lerman, Ubiquitin and ubiquitin-like proteins in protein regulation, Circ. Res. 100 (2007) 1276-1291.
101. J. Hwang, R.F. Kalejta, Human cytomegalovirus protein pp71 induces Daxx SUMOylation, J. Virol. 83 (2009) 6591-6598.
102. C. Kahana, G. Asher, Y. Shaul, Mechanisms of protein degradation: an odyssey with ODC, Cell Cycle 4 (2005) 1461-1464.
103. A.R. Fehr, D. Yu, Human cytomegalovirus gene UL21a encodes a short-lived cytoplasmic protein and facilitates virus replication in broblasts, J. Virol. 84 (2010) 291-302.
104. M.M.O. Peña, S.P. Melo, Y.-Y. Xing, K. White, K.W. Barbour, F.G. Berger, The intrinsically disordered n-terminal domain of thymidylate synthase targets the enzyme to the ubiquitin-independent proteasomal degradation path- way, J. Biol. Chem. 284 (2009) 31597-31607.
105. L.L. Bolin, L.K. Hanson, J.S. Slater, J.A. Kerry, A.E. Campbell, Murine cytomegalovirus US22 protein pM140 protects its binding partner, pM141, from proteasome-dependent but ubiquitin-independent degradation, J. Virol. 84 (2010) 2164-2168.
106. B. Ranger-Zisman, A. Palmon, S. Blagerman, S. Tel-Or, D. Benharroch, M. Pecht, N. Trainin, Y. Burstein, Novel therapeutic strategies against cytomegalovirus infection, Nat. Immun. 14 (1995) 250-261.
107. L.K. Hanson, J.S. Slater, Z. Karabekian, G. Ciocco-Schmitt, A.E. Campbell, Products of US22 genes M140 and M141 confer efcient replication of murine cytomegalovirus in macrophages and spleen, J. Virol. 75 (2001) 6292-6302.
108. M. Rechsteiner, S.W. Rogers, PEST sequences and regulation by proteolysis, Trends Biochem. Sci. 21 (1996) 267-271.
109. G. Siegl, Molecular biology and pathogenicity of human and animal parvoviruses, Behring Inst. Mitt. (1990) 6-13.
110. E. Ayuso, F. Mingozzi, F. Bosch, Production, purication and characterization of adeno-associated vectors, Curr. Gene Ther. 10 (2010) 423-436.
111. C.L. Miller, D.J. Pintel, The NS2 protein generated by the parvovirus minute virus of mice is degraded by the proteasome in a manner independent of ubiquitin chain elongation or activation, Virology 285 (2001) 346-355.
112. L.K. Naeger, J. Cater, D.J. Pinte Thesmallnonstructuralprotein(NS2)oftheparvovirus minute virus of mice is required for efcient DNA replication and infectious virus production in a cell-type-specic manner, J. Virol. 64 (1990) 6166-6175.
113. S.F. Cotmore, A.M. D'Abramo Jr., L.F. Carbonell, J. Bratton, P. Tattersall, The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells, Virology 231 (1997) 267-280.
114. M.S. De Mitri, R. Cassini, M. Bernardi, Hepatitis B virus-related hepatocarci- nogenesis: molecular oncogenic potential of clear or occult infections, Eur. J. Cancer 46 (2010) 2178-2186.
115. T.S. Yen, Hepadnaviral X protein: review of recent progress, J. Biomed. Sci. 3 (1996) 20-30.
116. M.J. Bouchard, R.J. Schneider, The enigmatic X gene of hepatitis B virus, J. Virol. 78 (2004) 12725-12734.
117. C.M. Kim, K. Koike, I. Saito, T. Miyamura, G. Jay, HBx gene of hepatitis B virus induces liver cancer in transgenic mice, Nature 351 (1991) 317-320.
118. Z. Hu, Z. Zhang, E. Doo, O. Coux, A.L. Goldberg, T.J. Liang, Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex, J. Virol. 73 (1999) 7231-7240.
119. J.H. Kim, S.Y. Sohn, T.S. Benedict Yen, B.Y. Ahn, Ubiquitin-dependent and -independent proteasomal degradation of hepatitis B virus X protein, Biochem. Biophys. Res. Commun. 366 (2008) 1036-1042.
120. R. Stohwasser, H.G. Holzhutter, U. Lehmann, P. Henklein, P.M. Kloetzel, Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4/MC6 subunit, Biol. Chem. 384 (2003) 39-49.
121. Z. Zhang, N. Torii, A. Furusaka, N. Malayaman, Z. Hu, T.J. Liang, Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex, J. Biol. Chem. 275 (2000) 15157-15165.
122. O. Barak, A. Aronheim, Y. Shaul, HBV X protein targets HIV Tat-binding protein 1, Virology 283 (2001) 110-120.
123. M.E. Cheetham, A.J. Caplan, Structure, function and evolution of DnaJ: con- servation and adaptation of chaperone function, Cell Stress Chaperones 3 (1998) 28-36.
124. B.C. Braun, M. Glickman, R. Kraft, B. Dahlmann, P.M. Kloetzel, D. Finley, M. Schmidt, The base of the proteasome regulatory particle exhibits chaperone-like activity, Nat. Cell Biol. 1 (1999) 221-226.
125. S.Y. Sohn, J.H. Kim, K.W. Baek, W.S. Ryu, B.Y. Ahn, Turnover of hepatitis B virus X protein is facilitated by Hdj1, a human Hsp40/DnaJ protein, Biochem. Biophys. Res. Commun. 347 (2006) 764-768.
126. D.H. Lee, M.Y. Sherman, A.L. Goldberg, Involvement of the molecular chaperone Ydj1 in the ubiquitin-dependent degradation of short-lived and abnormal proteins in Saccharomyces cerevisiae, Mol. Cell. Biol. 16 (1996) 4773-4781.
127. R.C. Gallo, Human retroviruses after 20 years: a perspective from the past and prospects for their future control, Immunol. Rev. 185 (2002) 236-265.
128. S.G. Deeks, HIV infection, inammation, immunosenescence, and aging, Annu. Rev. Med. 62 (2011) 141-155.
129. S. Ramos da Silva, D. Elgui de Oliveira, HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies, Cancer Lett. 305 (2011) 175-185.
130. M. Zhou, M.A. Halanski, M.F. Radonovich, F. Kashanchi, J. Peng, D.H. Price, J.N. Brady, Tat modies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunode- ciency virus type 1 transcription, Mol. Cell. Biol. 20 (2000) 5077-5086.
131. R.K. Ghosh, S.M. Ghosh, S. Chawla, Recent advances in antiretroviral drugs, Expert. Opin. Pharmacother. 12 (2011) 31-46.
132. V. Bres, R.E. Kiernan, L.K. Linares, C. Chable-Bessia, O. Plechakova, C. Treand, S. Emiliani, J.M. Peloponese, K.T. Jeang,O.Coux,M.Scheffner,M.Benkirane, A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter, Nat. Cell Biol. 5 (2003) 754-761.
133. B. Gargano, M. Fiorillo, S. Amente, B. Majello, L. Lania, p14ARF is capable of promoting HIV-1 tat degradation, Cell Cycle 7 (2008) 1433-1439.
134. I. Mao, J. Liu, X. Li, H. Luo, REGgamma, a proteasome activator and beyond? Cell Mol. Life Sci. 65 (2008) 3971-3980.
135. G.S. Apcher, S. Heink, D. Zantopf, P.M. Kloetzel, H.P. Schmid, R.J. Mayer, E. Kruger, Human immunodeciency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits, FEBS Lett. 553 (2003) 200-204.
136. P. Nelbock, P. Dillon, A. Perkins, C. Rosen, A cDNA for a protein that interacts with the human immunodeciency virus Tat transactivator, Science 248 (1990) 1650-1653.
137. M.M Atsuoka, K.-T. Jeang, Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation, Nat. Rev. Cancer 7 (2007) 270-280.
138. M. Matsuoka, K.T. Jeang, Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy, Oncogene 30 (2011) 1379-1389.
139. J.K. Nyborg, D. Egan, N. Sharma, The HTLV-1 Tax protein: Revealing mechanisms of transcriptional activation through histone acetylation and nucleosome disassembly, Biochim. Biophys. Acta (BBA) - Gene Regul. Mech. 1799 (2010) 266-274.
140. O. Rosin, C. Koch, I. Schmitt, O.J. Semmes, K.-T. Jeang, R. Grassmann, A human T-cell leukemia virus Tax variant incapable of activating NF-κB retains its immortalizing potential for primary T-lymphocytes, J. Biol. Chem. 273 (1998) 6698-6703.
141. M.D. Robek, L. Ratner, Immortalization of CD4+ and CD8+ T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone, J. Virol. 73 (1999) 4856-4865.
142. R. Pozzatti, J. Vogel, G. Jay, The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells, Mol. Cell. Biol. 10 (1990) 413-417.
143. S.C. Sun, D.W. Ballard, Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases, Oncogene 18 (1999) 6948-6958.
144. H.L. Pahl, Activators and target genes of Rel/NF-kappaB transcription factors, Oncogene 18 (1999) 6853-6866.
145. J.L. Pomerantz, D. Baltimore, Two pathways to NF-[kappa]B, Mol. Cell 10 (2002) 693-695.
146. J.A. Brockman, D.C. Scherer, T.A. McKinsey, S.M. Hall, X. Qi, W.Y. Lee, D.W. Ballard, Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation, Mol. Cell. Biol. 15 (1995) 2809-2818.
147. D.C. Scherer, J.A. Brockman, Z. Chen, T. Maniatis, D.W. Ballard, Signal-induced degradation of I kappa B alpha requires site-specic ubiquitination, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11259-11263.
148. L. Petropoulos, J. Hiscott, Association between HTLV-1 Tax and I kappa B alpha is dependent on the I kappa B alpha phosphorylation state, Virology 252 (1998) 189-199.
149. R. Rousset, C. Desbois, F. Bantignies, P. Jalinot, Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome, Nature 381 (1996) 328-331.
150. K. Kehn, L. Fuente C de, K. Strouss, R. Berro, H. Jiang, J. Brady, R. Mahieux, A. Pumfery, M.E. Bottazzi, F. Kashanchi, The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation, Oncogene 24 (2005) 525-540.
151. J.M. Rollinger, M. Schmidtke, The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery, Med. Res. Rev. 31 (2011) 42-92.
152. E. Ehrenfeld, J. Modlin, K. Chumakov, Future of polio vaccines, Expert Rev. Vaccines 8 (2009) 899-905.
153. D. Moradpour, F. Penin, C.M. Rice, Replication of hepatitis C virus, Nat. Rev. Microbiol. 5 (2007) 453-463.
154. C. Giannini, C. Brechot, Hepatitis C virus biology, Cell Death Differ. 10 (Suppl 1) (2003) S27-S38.
155. M. Shirakura, K. Murakami, T. Ichimura, R. Suzuki, T. Shimoji, K. Fukuda, K. Abe, S. Sato, M. Fukasawa, Y. Yamakawa, M. Nishijima, K. Moriishi, Y. Matsuura, T. Wakita, T. Suzuki, P.M. Howley, T. Miyamura, I. Shoji, E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein, J. Virol. 81 (2007) 1174-1185.
156. R. Suzuki, K. Moriishi, K. Fukuda, M. Shirakura, K. Ishii, I. Shoji, T. Wakita, T. Miyamura, Y. Matsuura, T. Suzuki, Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism, J. Virol. 83 (2009) 2389-2392.
157. K. Moriishi, R. Mochizuki, K. Moriya, H. Miyamoto, Y. Mori, T. Abe, S. Murata, K. Tanaka, T. Miyamura, T. Suzuki, K. Koike, Y. Matsuura, Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1661-1666.
158. K. Yuksek, W.L. Chen, D. Chien, J.H. Ou, Ubiquitin-independent degradation of hepatitis C virus F protein, J. Virol. 83 (2009) 612-621.
159. M. Groll, M. Bajorek, A. Kohler, L. Moroder, D.M. Rubin, R. Huber, M.H. Glickman, D. Finley, A gated channel into the proteasome core particle, Nat. Struct. Biol. 7 (2000) 1062-1067.
160. N.P. Dantuma, A. Sharipo, M.G. Masucci, Avoiding proteasomal processing: the case of EBNA1, Curr. Top. Microbiol. Immunol. 269 (2002) 23-36.
161. S. LaFrazia, C. Amici, M.G. Santoro, Antiviralactivityofproteasomeinhibitorsinherpes simplex virus-1 infection: role of nuclear factor-kappaB, Antivir. Ther. 11 (2006) 995-1004.
162. U. Schubert, D.E. Ott, E.N. Chertova, R. Welker, U. Tessmer, M.F. Princiotta, J.R. Bennink, H.G. Krausslich, J.W. Yewdell, Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV- 2, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13057-13062.
163. S. Prosch, C. Priemer, C. Hoich, C. Liebenthaf, N. Babel, D.H. Kruger, H.D. Volk, Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation, Antivir. Ther. 8 (2003) 555-567.
164. R.N. Harty, M.E. Brown, J.P. McGettigan, G. Wang, H.R. Jayakar, J.M. Huibregtse, M.A. Whitt, M.J. Schnell, Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction, J. Virol. 75 (2001) 10623-10629.
165. H. Watanabe, Y. Tanaka, Y. Shimazu, F. Sugahara, M. Kuwayama, A. Hiramatsu, K. Kiyotani, T. Yoshida, T. Sakaguchi, Cell-specic inhibition of paramyxovirus maturation by proteasome inhibitors, Microbiol. Immunol. 49 (2005) 835-844.